I am writing in response to the case report of Drs Gavras and Gavras titled "Are Patients Who Develop Angioedema With ACE Inhibition at Risk of the Same Problem With AT1 Receptor Blockers?"1 The authors report a small sampling of patients who had angioedema with ACE inhibition, but who subsequently tolerated ARB medications without adverse effects. They state that there findings "should alleviate the concerns of physicians who may be reluctant to use an ARB in such patients, despite anticipated benefits." Further, they state, "We are not aware of any report about patients who developed angioedema while receiving ACE inhibition and who were subsequently treated with an ARB." A search of the literature would suggest otherwise. In the ARCHIVES in 1998, Van Rijnsoever et al2 reported 13 cases of angioedema in patients taking losartan. Three of these individuals had previously reported angioedema while using an ACE inhibitor. Warner et al3 reported that 32% of individuals who experienced angioedema with ARB use had experienced a prior episode of angioedema attributed to ACE inhibitor therapy. In a review of the safety of ARB use in patients with ACE-induced angioedema, Howes and Tran4 state that "angiotensin receptor antagonists cannot be considered to be a safe alternative therapy in patients who have previously experienced ACE inhibitor-associated angioedema."4 The incidence of angioedema in patients taking ARBs is clearly lower than that seen with ACE inhibitors. However, the use of ARBs in patients who have previously experienced angioedema with ACE inhibitors should be undertaken with caution.1,4- 6
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.